Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Receivables (2023 - 2025)

Bioregenx has reported Receivables over the past 3 years, most recently at $39718.0 for Q4 2025.

  • For Q4 2025, Receivables fell 80.53% year-over-year to $39718.0; the TTM value through Dec 2025 reached $39718.0, down 80.53%, while the annual FY2025 figure was $39718.0, 80.53% down from the prior year.
  • Receivables for Q4 2025 was $39718.0 at Bioregenx, down from $62610.0 in the prior quarter.
  • Over five years, Receivables peaked at $203992.0 in Q4 2024 and troughed at $10943.0 in Q2 2024.
  • A 3-year average of $53859.0 and a median of $21115.0 in 2025 define the central range for Receivables.
  • On a YoY basis, Receivables climbed as much as 222.03% in 2025 and fell as far as 80.53% in 2025.
  • Year by year, Receivables stood at $104581.0 in 2023, then surged by 95.06% to $203992.0 in 2024, then plummeted by 80.53% to $39718.0 in 2025.
  • Business Quant data shows Receivables for BRGX at $39718.0 in Q4 2025, $62610.0 in Q3 2025, and $21115.0 in Q2 2025.